Get the Stockscreener App
100.48
1.00%
-1.02
After Hours:
100.05
-0.43
-0.43%
Incyte Corp stock is traded at $100.48, with a volume of 1.39M.
It is down -1.00% in the last 24 hours and down -2.37% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$101.50
Open:
$101.38
24h Volume:
1.39M
Relative Volume:
0.67
Market Cap:
$19.73B
Revenue:
$4.58B
Net Income/Loss:
$870.87M
P/E Ratio:
22.84
EPS:
4.3988
Net Cash Flow:
$945.58M
1W Performance:
-4.89%
1M Performance:
-2.37%
6M Performance:
+49.04%
1Y Performance:
+34.66%
1-Day Range:
$99.69
$102.47
1-Week Range:
$99.69
$106.99
52-Week Range:
$53.56
$109.28
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
100.48 | 19.93B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-01-25 | Initiated | Barclays | Overweight |
| Jun-16-25 | Upgrade | Stifel | Hold → Buy |
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Insider Selling: Incyte (NASDAQ:INCY) EVP Sells 20,105 Shares of Stock - MarketBeat
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 3, 2025 - BioSpace
Global Vitiligo Foundation Applauds Partnership Between Incyte and Winnie Harlow to Elevate Awareness and Understanding of Vitiligo - Yahoo Finance
Myeloproliferative Disorder Treatment Market Size Report 2032 - openPR.com
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding - Business Wire
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel - BioSpace
Incyte (INCY): Evaluating Valuation Following Recent Share Price Momentum - Yahoo Finance
Incyte appoints Richard Hoffman as executive VP and general counsel By Investing.com - Investing.com Nigeria
CACS Drug Market Accelerates at 3.9% CAGR to 2033, Reaching USD - openPR.com
Incyte Sets December Investor Lineup as Pipeline Progress Draws Market Attention - MyChesCo
Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Incyte: This Profitable Biotech Trades Like A Melting Iceberg (NASDAQ:INCY) - Seeking Alpha
Incyte: Riding Jakafi, Bracing For Generic Headwinds (NASDAQ:INCY) - Seeking Alpha
Incyte’s principal accounting officer Tray Thomas sells $79k in stock - Investing.com
Incyte receives the first letter confirming compliance following the FDA’s Untitled Letter spree - Medical Marketing and Media
Opzelura From Incyte Corp. - Pharmacy Times
Incyte Outpaces Expectations And Raises Its Revenue Forecast - Finimize
Incyte Corp. Stock Climbs 4.1%, Outperforms Peers - 富途牛牛
Integra LifeSciences, Evolent Health, Incyte, iRhythm, and Clover Health Stocks Trade Up, What You Need To Know - Yahoo Finance
Incyte (INCY): Barclays Raises Price Target to $115, Maintains O - GuruFocus
Does Incyte's Expanding Drug Pipeline Signal an Opportunity Following a 46.8% Price Surge? - Yahoo Finance
Incyte (INCY) Tops Goldman Sachs' Hedge Fund Concentration List - GuruFocus
Officer Tray Files To Sell 169 Of Incyte Corp [INCY] - TradingView
Commit To Purchase Incyte At $87.50, Earn 12.3% Annualized Using Options - Nasdaq
Is Incyte Corporation (ICY) stock among top earnings playsJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com
Incyte to Present at Upcoming December 2025 Investor Conferences - BioSpace
Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Is Incyte Corporation (ICY) stock considered safe havenJuly 2025 Trade Ideas & AI Enhanced Execution Alerts - newser.com
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
Why Incyte (INCY) is a Top Value Stock for the Long-Term - Yahoo Finance
Incyte at Jefferies London: Strategic Shift to Diversification - Investing.com
Incyte Expands ‘Moments of Clarity’ With New Stories Spotlighting Chronic Skin Conditions - MyChesCo
Incyte Stock Outlook: Is Wall Street Bullish or Bearish? - MSN
VP Denton Files To Sell 278 Of Incyte Corp [INCY] - TradingView
Is Incyte Corporation building a consolidation baseEarnings Recap Report & Verified Chart Pattern Signals - newser.com
Incyte (INCY) Receives Positive Opinion for Minjuvi in Europe - GuruFocus
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL) - BioSpace
Incyte corp EVP Steven Stein sells shares worth $897,866 - MSN
Can Incyte Corporation (ICY) stock attract analyst upgradesEarnings Trend Report & Reliable Entry Point Trade Alerts - newser.com
Forecasting Incyte Corporation price range with options dataJuly 2025 Outlook & Fast Entry High Yield Tips - newser.com
STATE STREET CORP Reduces Stake in Incyte Corp: A Strategic Port - GuruFocus
What risks investors should watch in Incyte Corporation stockTreasury Yields & AI Powered Market Entry Ideas - newser.com
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte Corp. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Key metrics from Incyte Corporation’s quarterly dataJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Why Analysts See Incyte’s Story Shifting as Pipeline Progress Drives New Valuation Targets - Yahoo Finance
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Incyte Corporation stock see PE expansionQuarterly Growth Report & Weekly High Return Opportunities - newser.com
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte Prepares to Showcase Pipeline Momentum With New mutCALR Data at ASH 2025 - MyChesCo
Incyte (INCY): Exploring Valuation After Recent Share Price Rally and Pipeline Progress - Yahoo Finance
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):